Why the study?
Does propafenone reduce ventricular ectopy compared to quinidine in patients with ventricular premature beats?
Does propafenone reduce ventricular ectopy compared to quinidine in patients with ventricular premature beats?
Propafenone is as effective as quinidine for reducing ventricular premature beats but is better tolerated, with fewer discontinuations due to side effects.
Answers are grounded in this paper and cite their sources.
Propafenone matches quinidine efficacy for ventricular ectopy with better tolerability; confirms its role as a viable alternative in this RCT.
The effectiveness of propafenone versus quinidine for the therapy of ventricular premature beats was evaluated in a placebo‐controlled double‐blind parallel study. A total of 105 patients was entered; 53 patients were randomly assigned to receive propafenone (600 mg/day and 900 mg/day during low‐and high‐dose weeks, respectively) and 52 patients were randomly assigned to receive quinidine (800 mg/day and 1,600 mg/day, respectively). Both drugs significantly reduced ventricular ectopy at both dose levels; there was no statistically significant difference between the two drugs in effectiveness, although a higher percentage of patients responded to propafenone. Side effects resulting in discontinuation of therapy were more common with quinidine. This study confirms the effectiveness of propafenone in the therapy of ventricular premature beats.
No takes yet. Share an insight, caveat, or question.
Morrison Hodges (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: